section name header

Pronunciation

ple-KAN-a-tide

Classifications

Therapeutic Classification: laxatives

Pharmacologic Classification: guanylate cyclase-C agonists

Indications

REMS


Action

  • Locally cyclic guanosine monophosphate concentrations, which intestinal fluid and accelerates transit time.
Therapeutic effects:
  • Increased frequency of complete spontaneous bowel movements.

Pharmacokinetics

Absorption: Minimally absorbed, action is primarily local.

Distribution: Stays within the GI tract with minimal distribution.

Metabolism/Excretion: Converted to its principal active metabolite within the GI tract. Plecanatide and active metabolite then degrade in intestinal lumen to smaller peptides and amino acids. Excretion information unknown.

Half-Life: Unknown.

Time/Action Profile

(improvement in symptoms)

ROUTEONSETPEAKDURATION
PO1 wk2–12 wk2 wk



Following discontinuation.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

GI: liver enzymes, abdominal distention, diarrhea, flatulence

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Trulance